Navigating Treatment: From Standard Care to Targeted Therapy

When steroids fail to bring the kidneys into remission, the goal of treatment shifts. Your care team is no longer looking for a “quick fix” with steroids; instead, they are moving toward a strategy designed to stabilize the kidney’s filters (podocytes) and reduce protein leakage over the long term.

Treatment for Steroid-Resistant Nephrotic Syndrome (SRNS) is divided into two main categories: immunosuppression (to quiet an overactive immune system in presumed primary cases) and supportive care (to protect the kidney tissue and manage symptoms) ^[1][2].

Critical Safety Warning: Never stop, taper, or adjust steroids or other immunosuppressants on your own. Abruptly stopping steroids can cause a life-threatening adrenal crisis or a disease flare. Your team will manage any required medication tapers safely.

First-Line Immunosuppression: Calcineurin Inhibitors (CNIs)

For patients with non-genetic (presumed primary) SRNS, calcineurin inhibitors (CNIs) are often recommended as the initial second-line treatment in appropriate patients ^[3][1]. These medications work by blocking a specific protein that tells the immune system to attack.

• Tacrolimus and Cyclosporine: These are the two primary CNIs used. Research shows that both can be effective, with some pediatric cohort studies reporting complete or partial remission in about 70% of children using them, though response varies by age and clinical features ^[1][4].
• Which is better? Studies have found that tacrolimus and cyclosporine have similar success rates ^[5][6]. However, tacrolimus is often preferred because it is less likely to cause side effects like hypertrichosis (excessive hair growth) or gingival hyperplasia (swelling of the gums) ^[6][7].
• Monitoring and Safety: These drugs require regular blood tests to check “trough” levels—ensuring there is enough medicine to work but not so much that it damages the kidneys (nephrotoxicity) ^[8][1]. They can also cause high blood pressure, increase potassium, and cause tremors.

Protecting the Filter: ACE Inhibitors and ARBs

While CNIs address the immune system, doctors also use medications originally designed for blood pressure to protect the kidneys directly. These are ACE inhibitors (like lisinopril) and Angiotensin Receptor Blockers (ARBs) (like losartan) ^[1][9].

These drugs are “supportive” rather than “curative.” They help by lowering the pressure inside the kidney’s filters, which can physically reduce the amount of protein that leaks out ^[10][9]. Even if a patient is not in full remission, staying on these medications can help preserve kidney function over time ^[2][11]. Important Note: ACE inhibitors and ARBs can worsen kidney function during dehydration. Ask your doctor for a written “sick day” plan for when to pause these medications if you have severe vomiting or diarrhea. Also, avoid NSAIDs (like ibuprofen) unless approved by your team.

When Genetics Change the Plan

If genetic testing confirms a monogenic (single-gene) cause for SRNS, the treatment plan often changes significantly.

• Avoiding Toxicity: Most genetic forms of SRNS do not respond to intensive immune-suppressing drugs ^[12]. Knowing this allows doctors to formulate a safe plan to stop or avoid high-dose medications that carry heavy side effects but offer little benefit ^[2].
• Targeted Supplements: In rare cases where SRNS is caused by a confirmed “CoQ10 pathway” mutation (such as COQ6 or ADCK4), specialist-directed high-dose Coenzyme Q10 supplements may be used. Some patients have seen significant protein reduction or even clinical resolution with this targeted approach ^[13][14].

Second-Line and ‘Rescue’ Options

If CNIs do not work, or if they cause severe side effects, other medications may be considered, though they are often off-label for SRNS and carry varying levels of evidence:

• Rituximab: This is a biological therapy that targets specific immune cells. While very effective for patients who respond to steroids (steroid-sensitive), its success in true steroid-resistant cases is more limited and varies widely ^[15][16].
• Mycophenolate Mofetil (MMF): MMF is sometimes used to help maintain remission, but research suggests it is generally less effective than continuing a CNI in children who have already responded to treatment ^[17].
• Cyclophosphamide: Once a common treatment, it is now used less frequently because it has lower remission rates compared to CNIs in most SRNS trials ^[15]. It is sometimes reserved as a “rescue” therapy for specific cases ^[18]. Newer agents like ofatumumab are currently highly experimental for this condition.

Your treatment path is a marathon, not a sprint. It often takes up to six months of consistent CNI treatment to determine if a patient will respond ^[19], though severe side effects or worsening kidney function may prompt your team to alter the plan sooner. During this time, close communication with your nephrology team about lab results and side effects is your most important tool.